By Kent Heckenlively, Esq.
In November of 1995, Dr. W. John Martin, chief of the Immunology/Molecular Pathology Unit at the Los Angeles County Medical Center, as well as a Professor of Pathology at the University of Southern California, presented findings to the Institute of Medicine suggesting that the polio vaccine had been contaminated with simian cytomegalovirus from African Green Monkeys. (The polio vaccine was cultured in kidney tissue from African Green Monkeys.)
Dr. Martin was concerned because his research suggested that the virus was spreading from infected individuals and causing a wide range of neurological problems. Yet the virus was not activating any of the typical inflammatory markers, thus causing medical practitioners to miss the problem. He referred to this virus as a “stealth adapted virus” because of its ability to evade the body’s immune responses.
According to Dr. Martin, his unsolicited proposals to the FDA and CDC to test polio vaccine lots for the simian cytomegalovirus were so threatening to the medical establishment that his laboratory at USC was closed and his research funding confiscated. Despite the great toll this research had taken on his professional life, Dr. Martin continued to pursue these stealth adapted viruses.
Using his own personal support, Dr. Martin was able to identify the presence of a stealth adapted virus in the brain biopsy of a child with neurological problems, who later died. An account of this can be found in the article “Complex Intracellular Inclusions in the Brain of a Child with a Stealth Virus Encephalopathy” and is available online at www.sciencedirect.com.
Looking at the samples from this child under a high-powered electron microscope, one thing which was immediately apparent was that these stealth viruses were damaging the mitochondria, the body’s powerhouse for cellular energy.
Dr. Martin first became interested in autism as a result of treating women with chronic fatigue syndrome. He noted that some of these mothers had children with autism. Could an infectious agent be passed from mother to child? Dr. Martin was led further along this path by the reported observation of abnormal head growth during the first year of life in children who were subsequently diagnosed with autism, as well as abnormal neuropeptide levels from cord blood.
It was apparent to Dr. Martin that these children were entering the world with significant challenges, which may have been exacerbated by their vaccines or other environmental exposures.
Early in his research Dr. Martin worked with Zaki Saluhuddin, a co-discoverer of the HHV-6 virus. They realized that stealth adaptation could potentially occur with all types of human and animal viruses, but that the use of vaccines had likely greatly increased the prevalence of infections caused by such viruses. Dr. Martin published a study along with Dr. Tom Glass showing that patient-derived stealth-adapted viruses caused severe neurological disease when inoculated into animals, without any accompanying inflammatory reaction, the accepted hallmark of an infectious disease.
Based on numerous virus cultures, and confirmed by Zaki Salahuddin, direct evidence for a stealth adapted virus infection was seen in the vast majority of patients with autism. A research article describing this finding was published in 1995. In his opinion “an autistic or severely learning disabled child should be considered as being stealth virus infected unless a negative culture shows otherwise.”
Martin believes that these stealth viruses strike at the mitochondria, causing the severe damage of autism and other neurological problems. The mitochondria insufficiency renders the child susceptible to environmental challenges that can place further demands on the body’s energy needs. Unfortunately, the immune system is relatively powerless to deal with stealth adapted viruses.
However, the body can potentially respond through what Dr. Martin calls the alternative cellular energy (ACE) pathway. Martin believes that in addition to food metabolism via the mitochondria, the body has another means of acquiring cellular energy that is somewhat similar to photosynthesis. He compares the ACE pathway to an electrical system of batteries, switches, and currents.
With the help of Mr. BJ McKelvie, Dr. Martin is supporting a transparent double-blind investigational research study to evaluate the safety and effectiveness of a non-drug approach to activate the body’s ACE pathway. Parents participating in the study are openly reporting on their findings and many are seeing quite remarkable improvements.
The therapy is performed in a child’s home, and consists of putting a dye activated ACE-like material on a thin paper towel placed upon a plastic sheet laid onto the child’s skin. The material is illuminated for 30-60 minutes with an ultraviolet light. The procedure can be repeated over several days, with many improvements being noted even after the first treatment. The cost for those who can afford to pay for the study is $350, and includes the materials, including the light, training video and compilation of results. Tax deductible donations are being sought for those who cannot afford the present cost.
Parents are required to fill out very detailed weekly journals on their child’s progress and to provide summaries, which can be read in their entirety at www.acepathway.ca. Parents are claiming that among the documented results are markedly improved social interactions with far better eye contact, verbal speech, reading ability, attention span, and in one patient, the control of previously uncontrollable seizures, allowing for the discontinuation of seizure medication.
Dr. Martin is confident that, although still investigational, this therapy promises a low cost and effective approach to treating children with autism. Jump starting the ACE pathway can help suppress the underlying viral infection, allowing normal mitochondrial function to resume, along with normal development. He is aware of reported recoveries of children from changes in diet, chelation, hyperbaric chambers, etc., but feels that these methods only rarely achieve the levels of recovery occurring with direct stimulation of the ACE pathway.
Kent Heckenlively is Legal Editor for Age of Autism.